{"id":"trifluridine-tipiracil-regorafenib","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Trifluridine/tipiracil (TAS-102) is a nucleoside analog that incorporates into DNA and inhibits thymidylate synthase, disrupting DNA synthesis in cancer cells. Regorafenib is a multikinase inhibitor that blocks VEGFR, FGFR, and other kinases involved in angiogenesis and tumor cell proliferation. The combination leverages complementary mechanisms: direct cytotoxicity plus anti-angiogenic and anti-proliferative effects.","oneSentence":"This combination pairs a nucleoside analog that inhibits thymidylate synthase with a multikinase inhibitor targeting angiogenesis and tumor growth pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:08.357Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (Phase 3 trial)"}]},"trialDetails":[{"nctId":"NCT07483684","phase":"PHASE3","title":"A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"HER2 IHC3+ Advanced Colorectal Cancer","enrollment":142},{"nctId":"NCT06137170","phase":"","title":"A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-03-01","conditions":"Metastatic Colorectal Cancer","enrollment":121},{"nctId":"NCT05198934","phase":"PHASE3","title":"Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-04-19","conditions":"Colorectal Cancer (CRC)","enrollment":160},{"nctId":"NCT04776148","phase":"PHASE3","title":"Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-03-29","conditions":"Colorectal Neoplasms","enrollment":563},{"nctId":"NCT07353268","phase":"PHASE2","title":"Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-21","conditions":"Colorectal Cancer","enrollment":76},{"nctId":"NCT03844620","phase":"PHASE2","title":"Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-29","conditions":"Refractory Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8","enrollment":100},{"nctId":"NCT05600309","phase":"PHASE3","title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-06-14","conditions":"Colorectal Cancer","enrollment":94},{"nctId":"NCT05839951","phase":"","title":"An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-04-24","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":818},{"nctId":"NCT05064059","phase":"PHASE3","title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-11-10","conditions":"Colorectal Cancer","enrollment":441},{"nctId":"NCT05608044","phase":"PHASE2","title":"A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agenus Inc.","startDate":"2022-11-30","conditions":"Metastatic Colorectal Cancer","enrollment":234},{"nctId":"NCT06887218","phase":"PHASE2","title":"5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-05-08","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":57},{"nctId":"NCT05328908","phase":"PHASE3","title":"A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2022-04-28","conditions":"Colorectal Neoplasms","enrollment":770},{"nctId":"NCT06199973","phase":"PHASE3","title":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-03-01","conditions":"Advanced Colorectal Cancer","enrollment":130},{"nctId":"NCT04879368","phase":"PHASE3","title":"RegoNivo vs Standard of Care Chemotherapy in AGOC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-06-01","conditions":"Gastro-Oesophageal Cancer","enrollment":450},{"nctId":"NCT06992648","phase":"PHASE3","title":"Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-04-01","conditions":"Colorectal Cancer Metastatic, Colorectal Cancer Recurrent","enrollment":302},{"nctId":"NCT05312398","phase":"PHASE2","title":"CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2021-07-15","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":219},{"nctId":"NCT04450836","phase":"PHASE2","title":"Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"UNICANCER","startDate":"2020-11-23","conditions":"Metastatic Colorectal Cancer","enrollment":234},{"nctId":"NCT04701476","phase":"PHASE2","title":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","status":"RECRUITING","sponsor":"Teclison Ltd.","startDate":"2021-05-20","conditions":"Colorectal Cancer; Lung Cancer","enrollment":110},{"nctId":"NCT03251378","phase":"PHASE1","title":"A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2017-12-11","conditions":"Advanced Solid Tumors, Metastatic Colon Cancer, Metastatic Breast Cancer","enrollment":129},{"nctId":"NCT05189171","phase":"","title":"MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer","status":"COMPLETED","sponsor":"Xilis, Inc.","startDate":"2022-10-25","conditions":"Colorectal Neoplasms","enrollment":46},{"nctId":"NCT03992456","phase":"PHASE2","title":"Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2020-04-24","conditions":"Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma","enrollment":12},{"nctId":"NCT05970705","phase":"PHASE2","title":"Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-07-01","conditions":"Metastatic Colorectal Cancer","enrollment":101},{"nctId":"NCT05278351","phase":"PHASE2","title":"Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-07-13","conditions":"Colorectal Neoplasms Malignant","enrollment":87},{"nctId":"NCT03305913","phase":"PHASE1","title":"Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2017-07-31","conditions":"Pretreated Metastatic Colorectal Cancer","enrollment":12},{"nctId":"NCT01896856","phase":"PHASE1, PHASE2","title":"Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-10-23","conditions":"Previously Treated Metastatic Colorectal Cancer","enrollment":118}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":194,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Trifluridine/Tipiracil + Regorafenib","genericName":"Trifluridine/Tipiracil + Regorafenib","companyName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","companyId":"second-affiliated-hospital-school-of-medicine-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination pairs a nucleoside analog that inhibits thymidylate synthase with a multikinase inhibitor targeting angiogenesis and tumor growth pathways. Used for Metastatic colorectal cancer (Phase 3 trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}